Moleculin says pooled ASCO data show no detectable cardiotoxicity with Annamycin at high cumulative exposure

Moleculin Biotech, Inc.

MBRX

0.00

Moleculin Biotech presented ASCO 2026 data from a pooled analysis of five completed trials of Annamycin in AML or soft tissue sarcoma.
The analysis found no detectable signs of drug-related heart damage, even at exposure levels above conventional lifetime anthracycline limits.
An independent Cleveland Clinic cardiac review supported the safety conclusion, strengthening the program’s risk-benefit profile for broader use.
The update underpins the ongoing Phase 2b/3 MIRACLE trial of AnnAraC in relapsed or refractory AML, with first 45 patients due to unblind in June 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605290821PRIMZONEFULLFEED9728522) on May 29, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.